Stock LEXARIA CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Lexaria Corp Other OTC

Equities

US52886N2080

Pharmaceuticals

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for Lexaria Corp
05/06 Lexaria Bioscience Corp. Announces Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study CI
05/06 Lexaria Bioscience Completes Dosing in Second Round of Semaglutide Formulations Human Pilot Study MT

Business Summary

Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company is engaged in pursuing the enhancement of the bioavailability of a diverse and a range of active pharmaceutical ingredients (API) using DehydraTECH, its patented proprietary drug delivery technology. The Company’s patented drug delivery technology, DehydraTECH, is designed to improve the way active molecules enter the bloodstream upon oral ingestion. DehydraTECH has also demonstrated enhanced delivery of certain active molecules into brain tissue. The Company has also developed DehydraTECH formulations for other applications demonstrating bio-absorption when administered intraorally and topically. It operates through two segments: Intellectual Property and Products. It also operates a licensed in-house research laboratory and holds an intellectual property portfolio with 35 patents granted and many patents pending worldwide. Its subsidiaries include Lexaria CanPharm ULC, and Lexaria CanPharm Holdings Corp.

Sales per Business

USD in Million2022Weight2023Weight Delta
Intellectual Property Licensing
64.9 %
0 21.4 % 0 64.9 % +169.06%
Business-to-business Product
19.5 %
0 44.4 % 0 19.5 % -61.07%
Research & Development
15.6 %
0 21.5 % 0 15.6 % -35.69%

Sales per region

USD in Million2022Weight2023Weight Delta
United States and Canada
100.0 %
0 100.0 % 0 100.0 % -11.43%

Managers

Managers TitleAgeSince
Christopher Bunka CEO
 Chief Executive Officer 62 26/06/26
John Docherty PSD
 President 53 15/15/15
George Jurcic IRC
 Investor Relations Contact - 01/21/01
Vanessa Carle LAW
 General Counsel - 01/19/01

Members of the board

Members of the board TitleAgeSince
Christopher Bunka CEO
 Chief Executive Officer 62 26/06/26
Nicholas Baxter BRD
 Director/Board Member 70 08/11/08
Albert Reese BRD
 Director/Board Member 74 14/21/14
John Docherty PSD
 President 53 15/15/15
William McKechnie BRD
 Director/Board Member 76 16/15/16
Catherine Turkel BRD
 Director/Board Member 63 02/22/02

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 12,885,673 12,677,868 ( 98.39 %) 0 98.39 %

Shareholders

NameEquities%Valuation
Wayne W Boos
7.916 %
1,020,000 7.916 % 4 M $
Christopher Bunka
4.097 %
527,955 4.097 % 2 M $
Invenomic Capital Management LP
3.673 %
473,265 3.673 % 2 M $
Geode Capital Management LLC
0.7709 %
99,338 0.7709 % 386 425 $
Vanguard Group, Inc. (Subfiler)
0.6609 %
85,156 0.6609 % 331 257 $
Waystone Fund Management (IE) Ltd.
0.4974 %
64,093 0.4974 % 249 322 $
John Docherty
0.4197 %
54,075 0.4197 % 210 352 $
Raymond James Financial Services, Inc.
0.3069 %
39,550 0.3069 % 153 850 $
STATE STREET CORPORATION
0.3050 %
39,301 0.3050 % 152 881 $
Adar1 Capital Management LLC
0.2066 %
26,626 0.2066 % 103 575 $
NameEquities%Valuation
CVI Holdings LLC
-
41,651 - 62 060 $
Clear Street LLC
-
100 - 149 $
UBS Securities LLC
-
99 - 148 $

Company contact information

Lexaria Bioscience Corp.

740 McCurdy Road Suite 100

V1X 2P7, Kelowna

+

http://www.lexariabioscience.com
address Lexaria Corp

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.82% 797B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.85% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.88% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.95% 323B
ABBVIE INC. Stock AbbVie Inc.
+9.49% 300B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.05% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+0.98% 223B
AMGEN INC. Stock Amgen Inc.
+5.30% 163B
PFIZER, INC. Stock Pfizer, Inc.
-6.29% 153B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LEXX Stock
  4. Stock
  5. Company Lexaria Corp